Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and FT-2102 in IDH1-Mutated MDS or AML
NCT04013880Phase 2Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of olutasidenib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Vanderbilt-Ingram Cancer Center. Planned start Aug 2019; status: withdrawn.
02
Drugs
olutasidenib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04013880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013880.